ArticleChest2021
Persistent Lung Inflammation After Clinical Resolution of Community-Acquired Pneumonia as Measured by
Article in Chest, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 19 citations in OpenAlex.
- Persistently raised inflammatory markers in a patient with resolved lower respiratory tract infection: a diagnostic challenge.Oxford medical case reports · 2026Article
- Persistent lung and vascular inflammation in mild to moderate COVID-19 survivors detected by ¹⁸F-FDG PET/CT: A quantitative imaging study with implications for cardiovascular risk.European journal of nuclear medicine and molecular imaging · 2026Article
- Article
- Persistent systemic interleukin-6 elevation after community-acquired pneumonia is associated with one-year mortality.Respiratory research · 2025Observational
- Lung function trajectories in children with pulmonary TB and non-TB lower respiratory tract infections.IJTLD open · 2025Article
- Longitudinal profiling of host response and oropharyngeal respiratory microbiome reveals dynamic alterations during recovery from community-acquired pneumonia.Biosafety and health · 2025Article
- The Risk of Adverse Cardiac Events after Pneumonia in Patients with Coronary Artery Disease.Annals of the American Thoracic Society · 2025Article
- Increased risk of major adverse cardiovascular events in patients with deep and infected diabetes-related foot ulcers.Diabetologia · 2025Article
- The Development and Validation of Radiopharmaceuticals Targeting Bacterial Infection.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2023Article
- A multiple comorbidities mouse lung infection model inBiomedical reports · 2023Article
- Cardiovascular changes after pneumonia in a dual disease mouse model.Scientific reports · 2022Article
- A Metabolomics Approach to Sulforaphane Efficacy in Secondhand Smoking-Induced Pulmonary Damage in Mice.Metabolites · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 3 countries.
Funding
Abstract
backgroundSurvivors of community-acquired pneumonia (CAP) are at increased risk of cardiovascular disease, cognitive and functional decline, and death, but the mechanisms remain unknown. RESEARCH QUESTION: Do CAP survivors have evidence of increased inflammatory activity in their lung parenchyma on 2-deoxy-2-[ STUDY DESIGN AND
methodsWe obtained
resultsOverall, 68% of CAP survivors (95% CI, 45%-85%) had distinct residual areas of increased
interpretationAn important proportion of CAP survivors have persistent pulmonary foci of increased inflammatory activity beyond resolution of their infection. As inflammation contributes to cardiovascular disease, cognitive decline, functional waning, and mortality risk in the general population, this finding provides a plausible mechanism for the increased morbidity and mortality that have been observed post-CAP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.